|Awarded On||November 19, 2015|
|Title||Systematic identification of small molecule inhibitors that manipulate telomerase activities|
|Award Mechanism||Individual Investigator|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Zhou Songyang|
|Cancer Sites||All Sites|
The telomerase consists of the TERT enzyme and the TERC RNA template. Telomerase expression and activity are up-regulated in cancer cells, and telomerase dysregulation has been linked to poor prognosis and drug resistance. These studies indicate that the telomerase is an attractive target for anti-cancer therapies. Telomerase inhibition should specifically target tumor cells and work in a broad spectrum of cancers. Treating cancer cells with telomerase inhibitors, however, can provoke cells to adopt telomerase-independent mechanisms, leading to drug resistance. Here, we propose strategies that target regulatory pathways of the telomerase, not the telomerase itself. Specifically, we will targ...